CoChat
Sign Up
Cited by 104Schizophrenia research and treatmentTreatment of Major DepressionTryptophan and brain disorders

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

Khodaie-Ardakani, Mohammad-Reza, Mirshafiee, Omid, Farokhnia, Mehdi, Tajdini, Masih, Hosseini, Seyed-Mohammad-Reza, Modabbernia, Amirhossein, Rezaei, Farzin, Salehi, Bahman, Yekehtaz, Habibeh, Ashrafi, Mandana, Tabrizi, Mina, Akhondzadeh, Shahin·2014·Psychiatry Research
DOI 10.1016/j.psychres.2013.12.051
Open this paper in CoChat — free account

Abstract

The objective of this study was to assess the efficacy and tolerability of minocycline add-on to risperidone in treatment of negative symptoms of patients with chronic schizophrenia. In a randomized double-blind placebo-controlled study, 40 patients with chronic schizophrenia who were stabilized on risperidone for a minimum duration of eight weeks were recruited. The patients were randomly assigned to minocycline (titrated up to 200 mg/day) or placebo in addition to risperidone (maximum dose of 6 mg/day) for eight weeks. Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale, and Extrapyramidal Syndrome Rating Scale were used. Thirty-eight patients completed the study. Significant time × treatment interaction for negative [F(2.254,85.638)=59.046, P<0.001] general psychopathology [F(1.703,64.700)=6.819, P=0.001], and positive subscales [F(1.655,62.878)=5.193, P=0.012] as well as total PANSS scores [F(1.677,63.720)=28.420, P<0.001] were observed. The strongest predictors for change in negative symptoms were the treatment group (β=-0.94, t=-10.59, P<0.001) followed by the change in PANSS positive subscale (β=-0.185, t=-2.075, P=0.045). Side effect profiles of the two treatment regimens were not significantly different. Minocycline seems to be an efficacious and tolerable short-term add-on to risperidone for treatment of negative and general psychopathology symptoms of schizophrenia.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.psychres.2013.12.051

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 104

Related

See all

Metadata

Authors
Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S.
Affiliations
  • Razi Hospital (IR)
  • Roozbeh Hospital (IR)
  • Kurdistan University of Medical Sciences (IR)
  • Arak University of Medical Sciences (IR)
  • Tehran University of Medical Sciences (IR)
Corresponding author
Akhondzadeh, Shahin
ORCID
Venue
Psychiatry Research
Publisher
Elsevier BV
Published
2014-03
Volume
215
Issue
3
Pages
540-546
ISSN
0165-1781 (ISSN-L)
DOI
10.1016/j.psychres.2013.12.051
OpenAlex
W2070688969
Cited by
104
References
33
Citations by year
2026: 5 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 11 · 2020: 6 · 2019: 5 · 2018: 16 · 2017: 9 · 2016: 14 · 2015: 14 · 2014: 6
FWCI
10.94
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Psychiatry Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Tehran University of Medical Sciences (11921)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
minocycline, risperidone, schizophrenia, negative symptoms, adjunctive therapy, chronic schizophrenia, PANSS, extrapyramidal symptoms, depression, tolerability, neuroprotection
MeSH terms
Adult, Anti-Bacterial Agents, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Minocycline, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review